ProCE Banner Activity

TOURMALINE-MM1: Improved PFS With Ixazomib + Len/Dex in R/R MM

Slideset Download
Conference Coverage
Newly FDA approved ixazomib combination therapy with lenalidomide/dexamethasone prolongs PFS and increases response rate in patients with R/R MM.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen